Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induced pluripotent stem cell-derived natural killer cells: poised for the clinic as an off-the-shelf allogeneic cell therapy.

Translational cancer research·2026
Same author

Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development.

Nature communications·2026
Same author

No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.

Blood cancer discovery·2025
Same author

Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer.

Journal for immunotherapy of cancer·2025
Same author

Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy.

Nature immunology·2025
Same author

miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.

Nature communications·2025

Related Experiment Video

Updated: Jan 13, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.4K

Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.

Ruiheng Wang1,2, Jianhua Yu3,4,5, Michael A Caligiuri1,2,6

  • 1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, California.

Cancer Research
|January 6, 2026
PubMed
Summary
This summary is machine-generated.

In vivo chimeric antigen receptor (CAR)-T cell therapy engineers T cells inside the body, overcoming limitations of traditional ex vivo methods. This review explores novel delivery systems for enhanced CAR-T cell therapy accessibility and efficacy.

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

889
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

4.8K

Related Experiment Videos

Last Updated: Jan 13, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
08:04

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

12.4K
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

889
Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models
06:22

Author Spotlight: Enhancing CAR-T Cell Function in Syngeneic Tumor Models

Published on: February 2, 2024

4.8K

Area of Science:

  • Immunology
  • Biotechnology
  • Gene Therapy

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy shows promise for hematologic malignancies but faces manufacturing challenges.
  • Conventional ex vivo CAR-T production is costly, complex, and limits scalability and accessibility.

Purpose of the Study:

  • To review current in vivo CAR-T cell engineering strategies and delivery systems.
  • To discuss advancements in achieving efficient, specific, and safe CAR transgene transfer.
  • To explore challenges and future directions for in vivo CAR-T therapy.

Main Methods:

  • Review of viral vectors (lentiviruses, retroviruses, AAVs, viral-like particles) for in vivo CAR-T delivery.
  • Analysis of non-viral systems including lipid nanoparticles and polymer-based carriers.
  • Examination of vector tropism, membrane modifications, and targeting ligand design principles.

Main Results:

  • In vivo CAR-T engineering bypasses ex vivo manipulation, offering a potentially more accessible therapeutic approach.
  • Various viral and non-viral delivery platforms are being engineered for targeted CAR transgene expression.
  • Preclinical and clinical studies are evaluating the safety and efficacy of these in vivo strategies.

Conclusions:

  • In vivo CAR-T cell engineering presents a transformative alternative to ex vivo manufacturing.
  • Optimizing vector stability, T cell targeting, and reducing immunogenicity are key for clinical advancement.
  • Further development is crucial to broaden the clinical application of in vivo CAR-T therapies.